Immunohistochemical detection of phosphorylated JNK, p38 MAPK, and ERK5 in ameloblastic tumors

Journal of Oral Pathology and Medicine

Volumn 36, Issue 9, 2007, Pages 543-549

  Kumamoto, H ^a   Ooya, K ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

Ameloblastoma; Mitogen activated protein kinase (MAPK); Signal transduction

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE;

AMELOBLASTOMA; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TOOTH FLORA;

AMELOBLASTOMA; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; JAW NEOPLASMS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 7; MITOGEN-ACTIVATED PROTEIN KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; TOOTH GERM;

EID: 34548548454     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2007.00555.x     Document Type: Article

References (36)

1. Sciubba JJ, Fantasia JE, Kahn LB. Tumors and cysts of the jaw. Washington, DC : Armed Forces Institute of Pathology, 2001 71 99.
2. Philipsen HP, Reichart PA, Slootweg PJ, et al. Odontogenic tumours. In : Barnes L, Eveson JW, Reichart PA, Sidransky D, eds. WHO classification of tumours. Pathology and genetics. Head and neck tumours. Lyon : IARC Press, 2005 283 327.
3. Heikinheimo K, Jee KJ, Niini T, et al. Gene expression profiling of ameloblastoma and human tooth germ by means of a cDNA microarray. J Dent Res 2002 81 : 525 30.
4. Kumamoto H. Molecular pathology of odontogenic tumors. J Oral Pathol Med 2006 35 : 65 74.
5. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001 81 : 807 69.
6. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002 298 : 1911 2.
7. Adler V, Polotskaya A, Wagner F, Kraft AS. Affinity-purified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. J Biol Chem 1992 267 : 17001 5.
8. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994 265 : 808 11.
9. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995 270 : 1326 31.
10. Lee JD, Ulevitch RJ, Han J. Primary structure of BMK1: a new mammalian map kinase. Biochem Biophys Res Commun 1995 213 : 715 24.
11. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001 22 : 153 83.
12. Pearson G, English JM, White MA, Cobb MH. ERK5 and ERK2 cooperate to regulate NF-κB and cell transformation. J Biol Chem 2001 276 : 7927 31.
13. Nishitoh H, Matsuzawa A, Tobiume K, et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. Genes Dev 2002 16 : 1345 55.
14. Antonyak MA, Kenyon LC, Godwin AK, et al. Elevated JNK activation contributes to the pathogenesis of human brain tumors. Oncogene 2002 21 : 5038 46.
15. Elenitoba-Johnson KS, Jenson SD, Abbott RT, et al. Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc Natl Acad Sci U S A 2003 100 : 7259 64.
16. Kumamoto H, Takahashi N, Ooya K. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas. J Oral Pathol Med 2004 33 : 360 7.
17. Watson FL, Heerssen HM, Bhattacharyya A, Klesse L, Lin MZ, Segal RA. Neurotrophins use the Erk5 pathway to mediate a retrograde survival response. Nat Neurosci 2001 4 : 981 8.
18. Hayashi M, Fearns C, Eliceiri B, Yang Y, Lee JD. Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res 2005 65 : 7699 706.
19. Xia Y, Karin M. The control of cell motility and epithelial morphogenesis by Jun kinases. Trends Cell Biol 2004 14 : 94 101.
20. Nebreda AR, Porras A. p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000 25 : 257 60.
21. Sabapathy K, Jochum W, Hochedlinger K, Chang L, Karin M, Wagner EF. Defective neural tube morphogenesis and altered apoptosis in the absence of both JNK1 and JNK2. Mech Dev 1999 89 : 115 24.
22. Ihle JN. The challenges of translating knockout phenotypes into gene function. Cell 2000 102 : 131 4.
23. Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K. Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. Proc Natl Acad Sci U S A 2002 99 : 9248 53.
24. Marques CA, Keil U, Bonert A, et al. Neurotoxic mechanisms caused by the Alzheimer's disease-linked Swedish amyloid precursor protein mutation: oxidative stress, caspases, and the JNK pathway. J Biol Chem 2003 278 : 28294 302.
25. Choi HJ, Lee SY, Cho Y, Hwang O. JNK activation by tetrahydrobiopterin: implication for Parkinson's disease. J Neurosci Res 2004 75 : 715 21.
26. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A 1995 92 : 11746 50.
27. Sandra F, Hendarmin L, Kukita T, Nakao Y, Nakamura N, Nakamura S. Ameloblastoma induces osteoclastogenesis: a possible role of ameloblastoma in expanding in the bone. Oral Oncol 2005 41 : 637 44.
28. Slootweg PJ. p53 protein and Ki-67 reactivity in epithelial odontogenic lesions. An immunohistochemical study. J Oral Pathol Med 1995 24 : 393 7.
29. Kumamoto H. Detection of apoptosis-related factors and apoptotic cells in ameloblastomas: analysis by immunohistochemistry and an in situ DNA nick end-labelling method. J Oral Pathol Med 1997 26 : 419 25.
30. Kumamoto H, Ooya K. Immunohistochemical analysis of bcl-2 family proteins in benign and malignant ameloblastomas. J Oral Pathol Med 1999 28 : 343 9.
31. Iyoda K, Sasaki Y, Horimoto M, et al. Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer 2003 97 : 3017 26.
32. Ricote M, Garcia-Tunon I, Bethencourt F, et al. The p38 transduction pathway in prostatic neoplasia. J Pathol 2006 208 : 401 7.
33. Kumamoto H, Kimi K, Ooya K. Immunohistochemical analysis of apoptosis-related factors (Fas, Fas ligand, caspase-3 and single-stranded DNA) in ameloblastomas. J Oral Pathol Med 2001 30 : 596 602.
34. Kumamoto H, Kimi K, Ooya K. Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med 2001 30 : 309 15.
35. Kumamoto H, Ohki K, Ooya K. Expression of p63 and p73 in ameloblastomas. J Oral Pathol Med 2005 34 : 220 6.
36. Kumamoto H, Ooya K. Immunohistochemical detection of retinoblastoma protein and E2 promoter-binding factor-1 in ameloblastomas. J Oral Pathol Med 2006 35 : 183 9.